2024
Psilocybin pulse regimen reduces cluster headache attack frequency in the blinded extension phase of a randomized controlled trial
Schindler E, Sewell R, Gottschalk C, Flynn L, Zhu Y, Pittman B, Cozzi N, D'Souza D. Psilocybin pulse regimen reduces cluster headache attack frequency in the blinded extension phase of a randomized controlled trial. Journal Of The Neurological Sciences 2024, 460: 122993. PMID: 38581739, DOI: 10.1016/j.jns.2024.122993.Peer-Reviewed Original ResearchMeSH KeywordsAdultCluster HeadacheDouble-Blind MethodFemaleHallucinogensHumansMaleMiddle AgedPsilocybinTreatment OutcomeConceptsAttack frequencyCluster headacheCluster headache attack frequencyExtension phaseEffects of repeated treatmentReduction of attack frequencyPlacebo-controlled studyHeadache attack frequencyAdministration of psilocybinRandomized controlled trialsDouble-blindPsilocybin administrationPulse regimenAdverse eventsPulse regimensHeadache diaryTherapeutic efficacyDrug sessionsPulse administrationHeadacheStudy participantsWeeks
2023
Calcitonin Gene–Related Peptide Monoclonal Antibodies and Risk of SARS-CoV-2 Infection and Severe COVID-19 Outcomes Among Veterans With Migraine Disorder
Wang K, Fenton B, Deng Y, Anthony S, Dao V, Schindler E, Lipton R, Guirguis A, Skanderson M, Seng E, Sico J. Calcitonin Gene–Related Peptide Monoclonal Antibodies and Risk of SARS-CoV-2 Infection and Severe COVID-19 Outcomes Among Veterans With Migraine Disorder. JAMA Network Open 2023, 6: e2326371. PMID: 37523183, PMCID: PMC10391301, DOI: 10.1001/jamanetworkopen.2023.26371.Peer-Reviewed Original ResearchConceptsCalcitonin gene-related peptideSARS-CoV-2 infectionSevere COVID-19 outcomesCGRP mAbsMechanical ventilationSupplemental oxygenCOVID-19 outcomesSARS-CoV-2Cohort studyCGRP antagonistMAIN OUTCOMEMigraine disordersPositive SARS-CoV-2 test resultSARS-CoV-2 test resultsCOVID-19Protocol hazard ratiosRetrospective cohort studyMonoclonal antibody treatmentGene-related peptideLikelihood of hospitalizationCourse of diseasePeptide monoclonal antibodyElectronic health recordsNeuroimmune modulatorCumulative incidence
2020
Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin
Schindler EAD, Sewell RA, Gottschalk CH, Luddy C, Flynn LT, Lindsey H, Pittman BP, Cozzi NV, D'Souza D. Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin. Neurotherapeutics 2020, 18: 534-543. PMID: 33184743, PMCID: PMC8116458, DOI: 10.1007/s13311-020-00962-y.Peer-Reviewed Original ResearchConceptsTherapeutic effectAdverse eventsSingle administrationPsychotropic effectsWeekly migraine daysSerious adverse eventsCross-over studyEffects of psilocybinOral placeboMigraine daysMigraine frequencyClinical effectsControlled StudyHeadache disordersMigraine headacheHeadache diaryDrug effectsDrug AdministrationNeuropsychiatric conditionsMigraineFinal analysisStudy proceduresReceptor ligandsWeeksAdministration
2018
Survey Analysis of the Use, Effectiveness, and Patient‐Reported Tolerability of Inhaled Oxygen Compared With Injectable Sumatriptan for the Acute Treatment of Cluster Headache
Schindler EAD, Wright DA, Weil MJ, Gottschalk CH, Pittman BP, Sico JJ. Survey Analysis of the Use, Effectiveness, and Patient‐Reported Tolerability of Inhaled Oxygen Compared With Injectable Sumatriptan for the Acute Treatment of Cluster Headache. Headache The Journal Of Head And Face Pain 2018, 58: 1568-1578. PMID: 30221765, DOI: 10.1111/head.13405.Peer-Reviewed Original ResearchConceptsInjectable sumatriptanCluster headacheAcute treatmentMedication responseOxygen deliverySide effectsPatient-reported side effectsSecondary analysisTherapeutic response rateCigarette smoking historyOptimization of therapyOptimal oxygen deliveryPositive predictorSmoking historyOxygen therapyCigarette smokingHeadache clinicTherapeutic optionsPatient populationPharmacologic interventionsTriptan medicationsComparable efficacyDaily attacksMale genderTherapeutic response
2015
Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey
Schindler EA, Gottschalk CH, Weil MJ, Shapiro RE, Wright DA, Sewell RA. Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey. Journal Of Psychoactive Drugs 2015, 47: 372-381. PMID: 26595349, DOI: 10.1080/02791072.2015.1107664.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCluster HeadacheFemaleHallucinogensHumansLysergic Acid DiethylamideMaleMiddle AgedPsilocybinConceptsCluster headacheIndoleamine hallucinogensConventional medicationsChronic cluster headachePain syndromePreventative medicationsAlternative medicationsLysergic acid diethylamideHeadache clinicConventional therapyCluster periodHeadacheMedicationsFinal analysisAcid diethylamideHallucinogensFurther investigationMost responsesSignificant numberAdditional evidenceParticipantsRemissionPatientsSyndromeClinic